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A robust and rapid xenograft model to assess efﬁcacy of
chemotherapeutic agents for human acute myeloid leukemia
E Saland1,2, H Boutzen1,2, R Castellano3,4,5,6, L Pouyet3,4,5,6, E Griessinger7,8, C Larrue1,2, F de Toni1,2, S Scotland1,2, M David1,2,
G Danet-Desnoyers9, F Vergez1,2, Y Barreira10, Y Collette3,4,5,6, C Récher1,2,11,12 and J-E Sarry1,2,12
Relevant preclinical mouse models are crucial to screen new therapeutic agents for acute myeloid leukemia (AML). Current in vivo
models based on the use of patient samples are not easy to establish and manipulate in the laboratory. Our objective was to
develop robust xenograft models of human AML using well-characterized cell lines as a more accessible and faster alternative to
those incorporating the use of patient-derived AML cells. Five widely used AML cell lines representing various AML subtypes were
transplanted and expanded into highly immunodeﬁcient non-obese diabetic/LtSz-severe combined immunodeﬁciency IL2Rγc
null
mice (for example, cell line-derived xenografts). We show here that bone marrow sublethal conditioning with busulfan or irradiation
has equal efﬁciency for the xenotransplantation of AML cell lines. Although higher number of injected AML cells did not change
tumor engraftment in bone marrow and spleen, it signiﬁcantly reduced the overall survival in mice for all tested AML cell lines. On
the basis of AML cell characteristics, these models also exhibited a broad range of overall mouse survival, engraftment, tissue
inﬁltration and aggressiveness. Thus, we have established a robust, rapid and straightforward in vivo model based on engraftment
behavior of AML cell lines, all vital prerequisites for testing new therapeutic agents in preclinical studies.
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INTRODUCTION
Acute myeloid leukemia (AML) is the most common adult acute
leukemia and is characterized by clonal expansion of immature
myeloblasts, initiating from rare leukemic stem or progenitor cells.
In Europe and the USA, the incidence and mortality rates of AML
are about 5 to 8/100.000 and 4 to 6/100.000 per year,
respectively.1 Despite a high rate of complete remission after
treatment with genotoxic agents, the relapse rate remains very
high and the prognosis very poor. Overall survival at 5 years is
~ 30–40% in patients younger than 60 years, and o20% in
patients over 60 years. Front-line chemotherapy is highly effective
in ablating leukemic cells, but distant relapses are observed in the
majority of patients, characterized by a refractory phase during
which no other treatment has shown any efﬁcacy thus far.
Relapses are caused by malignant cell regrowth initiated by
chemoresistant leukemic clones.2,3
This unfavorable situation leads to a strong need for new
therapeutic strategies, as well as relevant preclinical mouse
models in which to test them. We have previously established a
robust xenotransplantation model to study primary human AML
biology and stem cell function based on the engraftment of
primary AML samples into non-obese diabetic (NOD)/LtSz-severe
combined immunodeﬁciency (SCID) IL2Rγc
null (NSG) mice.4,5 These
highly immunodeﬁcient mice have the advantages of a longer life
span and higher levels of engraftment of human AML cells
compared with other immunocompromised mouse strains such as
SCID, NOD-SCID.4,6,7 However, this model is based on three-to-six
month-long experiments with a large excess of cells and requires
access to a biobank of diverse primary AML patient samples.
Moreover, extensive characterization of this xenograft model with
more commonly used and easily accessible AML cell lines has not
been reported to date in the same setting to compare models
in vivo. Herein, we report experimental conditions (bone marrow
preconditioning and injected cell number) for a faster and easier
preclinical mouse model of AML based on the xenotransplantation
of a panel of six adult and childhood human AML cell lines,
representing different FAB types, genetic variants and chromoso-
mal abnormalities. In addition, we have also shown that our cell
line-derived xenograft (CLDX as mirrored to patient-derived
xenograft) models exhibited a broad range of overall mice
survival, engraftment, tissue inﬁltration and aggressiveness based
on their AML cell line characteristics.
MATERIALS AND METHODS
Cell lines and culture conditions
Human AML cell lines U937, MV4-11, MOLM-14, HL-60 (DSMZ, Braunsch-
weig, Germany) and KG1a (ATCC, Manassas, VA, USA) were maintained in
minimum essential medium-α medium supplemented with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA, USA). All cell lines were grown
in the presence of 100 units per ml of penicillin and 100 μg/ml of
streptomycin, and were incubated at 37 °C with 5% CO2. The cultured cells
were split every 2–3 days and maintained in an exponential growth phase.
All cell lines were annually re-ordered to DSMZ or ATCC stocks and
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periodically authenticated by morphologic inspection and mutational
sequencing, and tested negative for Mycoplasma. The clinical and
mutational features of our AML cell lines are described in Table 1.
Flow cytometric analysis
CD45-APC (BD, San Jose, CA, USA; 555485), CD33-PE (BD 555450),
CD44-FITC (BD 555478), CD44-PE-Cy7 (BD 560533), CD45.1-PerCP-Cy5.5
(BD 560580), CD34-APC-Cy7 (Biolegend, Ozyme, Saint Quentin Yvelines,
France; 343514), Lin1-FITC (BD 340546), CD123-PE (BD 340545), CD45RA-
Alexa Fluor 700 (BD 560673) and CD38-APC (BD 555362) ﬂuorescent
antibodies were used to analyze leukemic cells before and after injection
into animals to determine phenotypic analysis of engrafted cells and
percentage of leukemic cell engraftment. Absolute cell counts were
determined with CountBright absolute counting beads (Invitrogen)
following the manufacturer's recommendations.
Xenotransplantation of human leukemic cells
Animals were used in accordance with a protocol reviewed and approved
by the Institutional Animal Care and User Ethical Committee of the
UMS006 and Région Midi-Pyrénées (Approval#13-U1037-JES08). NSG mice
were produced at the Genotoul Anexplo platform at Toulouse (France)
using breeders obtained from The Charles River Laboratory. Mice were
housed in sterile conditions using high-efﬁciency particulate arrestance
ﬁltered micro-isolators and fed with irradiated food and acidiﬁed water.
Adult mice (6–8 weeks old) were sublethally irradiated with 250 cGy of
total body irradiation or treated with 20mg/kg busulfan (Busilvex, Pierre
Fabre, France) by intraperitoneal administration 24 h before injection of
leukemic cells. Cultured AML cell lines were washed twice in phosphate-
buffered saline (PBS) and cleared of aggregates and debris using a 0.2-mm
cell ﬁlter, and suspended in PBS at a ﬁnal concentration of 0.2–2 million
cells per 200 μl of PBS per mouse for intravenous injection. Xenograft
tumors were generated by injecting AML cells (in 200 μl of PBS) in the tail
vein of NSG mice. Daily monitoring of mice for symptoms of disease
(rufﬂed coat, hunched back, weakness and reduced motility) determined
the time of killing for injected animals with signs of distress.
Hematopoietic cells count
Peripheral blood was obtained with retro-orbital bleeding. Fifty microliter
of blood were collected in heparin-coated collection tube for analyzed
with hematology counter (ABX Micros 60, Horiba, Montpellier, France).
Assessment of leukemic engraftment
NSG mice were humanely killed in accordance with the Institutional
Animal Care and User Ethical Committee of the UMS006 and Région Midi-
Pyrénées Protocols. Bone marrow (mixed from tibias and femurs) and
spleen were dissected, crushed in PBS and made into single cell
suspensions for analysis by ﬂow cytometry (FACS Calibur, FACS Canto,
FACS LSR II–BD Biosciences, San Jose, CA, USA).
Statistical analysis
Mann–Whitney test was used to calculate ﬁnal P-values. Signiﬁcance is
represented as followed: *Po0.05, **Po0.01 and ***Po0.005.
RESULTS AND DISCUSSION
The objective of this study was to develop robust xenograft
models by establishing the speciﬁc experimental conditions (cell
dose, dissemination tropism, growth kinetics, symptoms, lethality
and stability of cell surface markers) required for the evaluation of
therapeutic agents in routine and easy-to-use setting. The
advantages of using well-established AML cell lines as compared
with primary patient samples are the unlimited access to a large
amount of human AML cells and a faster engraftment in
immunodeﬁcient mice. We analyzed in vivo the ﬁve most
commonly used AML cell lines with a range of molecular
abnormalities, clinical, biological and immunophenotypical char-
acteristics (Table 1). MOLM-14 and MV4-11 cells are a widely
studied model for FLT3-ITD AML (30% of AML patients associated
with worst prognosis). U937 cells are a model for monocyticT
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development and translocation t(10;11)(p13;q14) leading to
PICALM-MLLZ10/AF10 fusion gene found in 7% of AML patients
with good prognosis factor. HL-60 cells are a model for human
myeloid promyelocytic cell differentiation and proliferation, and
KG1a is a model for immature myeloid progenitor phenotype and
FGFR1 kinase fusion genes (Table 1). These cells were transplanted
intravenously in adult NSG mice. Importantly, AML cell lines kill
mice as does AML in patients, whereas primary AML cells in NSG
mice rarely kill the animals.
Busulfan or irradiation conditioning step does not change the
xenotransplantation efﬁcacy of AML cells
Xenotransplantation of primary human AML or normal CD34+ cells
is greatly enhanced if recipients receive a chemical conditioning
regimen such as busulfan (a myeloablative alkylating agent,
25–35mg/kg) or total body irradiation (up to 4 Gy).8–11 However, it
is not clear whether conditioning improves the engraftment of
human AML cell lines especially in the most recently developed
NSG mouse model. We ﬁrst performed a maximally tolerated dose
study to deﬁne the best conditioning procedures (Figures 1a and b)
and then tested the effect of the determined sublethal conditions
(20 mg/kg busulfan vs 2.25 Gy irradiation) on NSG mice. Body
weight, hemoglobin, platelet number and white blood cell
number were monitored over 4 weeks following the conditioning
procedure. Irradiation severely impacts mice body weight and
blood counts, whereas busulfan injection has a milder effect on
these parameters (Figures 1c and f). In both the procedures,
normal mouse hematopoiesis is recovered 3 weeks post
conditioning.
We observed a signiﬁcant reduction in overall survival of the
xenografted mice in the busulfan conditioning setting as
compared with irradiation setting (Figure 2a) but observed no
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Figure 1. Impact of various bone marrow conditioning treatments on the overall and hematological toxicity and the engraftment efﬁcacy of
AML cell lines in highly immunodeﬁcient NSG mice. Kaplan–Meyer curve of the mice overall survival during the maximal tolerated dose
study (a, with irradiation dose escalade; b, with busulfan dose escalade). Adult NSG mice non-conditioned (n= 5) or irradiated at 2.25 Gy
(n= 5) or treated with 20mg/kg busulfan (n= 5) were weighed (c) and their blood was collected each week post conditioning for assays of
hemoglobin (d), platelets (e) and white blood cells (f).
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signiﬁcant difference in leukemic engraftment level in bone
marrow and spleen or total cell tumor burden after transplanta-
tion of four out the ﬁve AML (U937, KG1a, MOLM-14 and MV4-11)
cell lines tested (Figures 1b and e), as previously observed in NOD-
SCID for human cell engraftment. 11
AML cell lines exhibit a broad range of engraftment, tissue
inﬁltration and aggressiveness
A recurrent problem in leukemic adoptive transfer is the issue of
the cell dose injected, to avoid either engraftment failure or delay
or, on the contrary, a tumor burden outgrowth leading to a
premature animal death precluding any investigation. Thus, we
asked whether the cell number injected into NSG mice would
affect the overall mice survival. For 0.2 million injected AML cells,
recipient mice survival was dependent upon the AML cell line and
ranged from 28 to 68 days (U937oMOLM-14oMV4-11oHL-
60oKG1a; Figure 3a). As expected, increasing the injected cell
number (up to 2 M) decreased the overall mice survival for all AML
cell lines tested (Figure 3a). For both doses, U937 cells appeared to
be the most aggressive AML cell line, paralyzing and killing the
mice within 4 weeks, whereas mice engrafted with KG1a cells had
the longest overall survival with a median of 54 and 68 days for
2 M versus 0.2 M cells injected, respectively (Figure 3a).
The variability in mice survival between cell lines was not
associated with differences in leukemic cells inﬁltration in the
bone marrow (Figures 3b and c), spleen (Figure 3d) or the total
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Figure 2. Impact of the conditioning methods on the xenotransplantation of different AML cell lines in highly immunodeﬁcient
NSG mice. Adult NSG mice were injected with 2 × 106 of different AML cells (HL-60, MOLM-14, MV4-11, U937 and KG1a) 24 h post
conditioning (I, irradiation at 2.25 Gy; B, 20 mg/kg busulfan). Mice survival is analyzed with Kaplan–Meyer curve (a) and the engraftment
level is assessed by ﬂow cytometry in bone marrow (million, b; percent, c), spleen (million, d) and in bone marrow+spleen (total cell tumor
burden, e).
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tumor burden (Figure 3e), regardless of the injected leukemic cell
dose. Accordingly, decreasing injected cell number increases the
time to engraft without changing the engraftment capacity at the
dissection time and has the disadvantage of extending the in vivo
efﬁcacy assay. Furthermore, we noted a variable total cell tumor
burden in hematopoietic tissues (bone marrow and spleen)
depending on the AML cell line type (2 M for HL-60; 9 M, U937;
12 M for MOLM-14; 13 M, KG1a; and 30 M MV4-11; Figure 3e). The
engraftment level of HL-60 cells was lowest compared with other
cell lines. MV4-11 cells have the highest expansion level in
hematopoietic tissues of xenografted mice. Although most of the
AML cell lines invade the spleen and exhibit a spleenomegaly,
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Figure 3. Impact of the injected cell dose on the xenotransplantation of different AML cell lines in highly immunodeﬁcient NSG mice. NSG
mice were injected with two doses (0.2 or 2 Millions) of different AML cells (HL-60, MOLM-14, MV4-11, U937 and KG1a). Mice survival was
analyzed after xenotranplantation (a). The engraftment level was evaluated in the bone marrow (million, b; percent, c) and spleen (million, d),
as well as the total tumor cell burden in hematopoietic mice organs (million, e). Tumor invasion in hematopoietic organs was shown through
the spleen size (f) and the tissue distribution in hematopoietic organs (g). BM, bone marrow; SP, spleen. **Po0.01 and ***Po0.005.
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HL-60 and MOLM-14 cells are preferentially located in the bone
marrow (Figures 3f and g), indicating differential tissue tropism for
this panel of AML cell lines.
These results show a diversity of engraftment capacities and
aggressiveness in these AML cell lines, as well as a diversity in
tissue tropism, consistent with what we observed with AML
patient cells transplanted in the same immunodeﬁcient mice
strain.4 Engraftment levels, tissue distribution and overall survival
are not associated with any clinical features and cytogenetic
abnormalities. Interestingly, we also observed that AML cell lines
bearing differentiation markers such as U937, MOLM-14 and
MV4-11 appeared to have a more aggressive in vivo behavior than
immature like AML cell lines such as HL-60 or KG1a.
The overall immunophenotype of AML cells is conserved in vivo
We next addressed whether the immunophenotype of AML cell
lines was conserved in vivo. The expression level of various
myeloid cell surface markers such as CD45, CD33, CD44, CD34,
CD38, CD45RA and CD123 was analyzed for four AML cell lines
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Figure 4. Analysis of the expression of major myeloid cell surface markers in AML cell lines before and after xenotransplantation. The
immunophenotype of HL-60, MV4-11, U937 and KG1a cells was analyzed on BD LSRII Fortessa Flow Cytometer using human CD45, CD44,
CD33, CD34, CD38, CD45RA and CD123 before and after xenotransplantation in our NSG mice model. All AML cell lines are SSClow, CD45,
CD44 and CD33 positive in vitro and in vivo.
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before and after xenotransplantation (Figure 4). Most of those
markers appeared globally unchanged during engraftment,
however, we found that the transplantation of HL-60 cells in mice
also led to the appearance of a second population CD44dim
(Figure 4, second column). Moreover, the frequency of CD34+
CD38+ was signiﬁcantly increased in vivo to the detriment of the
CD34+CD38- population (Figure 4, third column). With the sole
exception of the CD38 marker, the NSG-based model of AML
maintains cell phenotype more consistently than in the NOD-SCID
model.12
Here we provide necessary technical details and conditions that
other laboratories may use to quickly and routinely set up in vivo
AML experiments. A xenografts based on native or engineered cell
lines are not novel, this is the ﬁrst study that compares the ﬁve
most well-characterized AML cell lines in the same experimental
settings and mouse strain. The establishment of this preclinical
AML model is of special relevance and signiﬁcance to drug-
sensitivity studies as in vitro cell culture-based screens do not
accurately reﬂect in vivo effects and responses. In conclusion, we
have found that the xenotransplantation models of ﬁve well-
characterized AML cell lines (for example, KG1a, HL-60, MOLM-14,
MV4-11 and U937) exhibited a broad range of mice survival,
engraftment, tissue inﬁltration and aggressiveness. By increasing
or decreasing the number of injected leukemic cells, we can
modulate mice survival without changing the tissue distribution of
leukemic cells and their engraftment in NSG mice. This work has
also shown that AML cell lines kill mice in a manner similar to that
as patients in clinics but different from the xenograft of primary
AML patient specimens in NSG mice. Moreover, in contrast to
patient-derived xenograft models, these CLDX models are a
powerful, rapid and straightforward in vivo assay available to all
leukemia research laboratories to perform preclinical studies to
assess the in vivo efﬁcacy of conventional or targeted therapies
in AML.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We thank all members of mice core facilities (UMS006, INSERM, Toulouse) for their
support and technical assistance and Dr. Mary Selak for helpful discussion and
reading of the manuscript. We thank Valérie Duplan-Eche, Delphine Lestrade and
Fatima L’Faqihi-Olive for technical assistance at the ﬂow cytometry core facility of
INSERM UMR1043. FdT is a fellowship from the Fondation de France. This work was
supported by grants from INSERM, Association Laurette Fugain (J-ES), Fondation ARC
(SFI20121205478; J-ES), Région Midi-Pyrénée (J-ES), the association G.A.E.L (CR) and
Fondation InNaBioSanté (CR and J-ES).
REFERENCES
1 Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid
leukemia. J Clin Oncol 2011; 29: 487–494.
2 Lübbert M, Müller-Tidow C, Hofmann WK, Koefﬂer HP. Advances in the treatment
of acute myeloid leukemia: from chromosomal aberrations to biologically
targeted therapy. J Cell Biochem 2008; 104: 2059–2070.
3 Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratiﬁcation,
and management. Am J Hemat 2012; 87: 89–99.
4 Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR et al. A robust
xenotransplantation model for acute myeloid leukemia. Leukemia 2009; 23:
2109–2117.
5 Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C et al. Human acute
myelogenous leukemia stem cells are rare and heterogeneous when assayed in
NOD/SCID/IL2Rγc-deﬁcient mice. J Clin Invest 2011; 121: 384–395.
6 Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute mye-
logenous leukemia progenitors that initiate malignant hematopoiesis in nonobese
diabetic/severe combined immunodeﬁcient mice. Blood 1999; 94: 1761–1772.
7 Lapidot T, Fajerman Y, Kollet O. Immune-deﬁcient SCID and NOD/SCID mice
models as functional assays for studying normal and malignant human hema-
topoiesis. J Mol Med 1997; 75: 664–673.
8 Mauch P, Down JD, Warhol M, Hellman S. Recipient preparation for bone marrow
transplantation. I. Efﬁcacy of total-body irradiation and busulfan. Transplantation
1988; 46: 205–210.
9 Down JD, Ploemacher RE. Transient and permanent engraftment potential of
murine hematopoietic stem cell subsets: differential effects of host conditioning
with gamma radiation and cytotoxic drugs. Exp Hematol 1993; 21: 913–921.
10 Ishikawa F, Livingston AG, Wingard JR, Si Nishikawa, Ogawa M. An assay for long-
term engrafting human hematopoietic cells based on newborn NOD/SCID/beta2-
microglobulin(null) mice. Exp Hematol 2002; 30: 488–494.
11 Robert-Richard E, Ged C, Ortet J, Santarelli X, Lamrissi-Garcia I, de Verneuil H et al.
Human cell engraftment after busulfan or irradiation conditioning of NOD/
SCID mice. Haematologica 2006; 91: 1384.
12 Henschler R, Göttig S, Junghahn I, Bug G, Seifried E, Müller AM et al.
Transplantation of human acute myeloid leukemia (AML) cells in immuno-
deﬁcient mice reveals altered cell surface phenotypes and expression of human
endothelial markers. Leuk Res 2005; 29: 1191–1199.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
CLDX models for AML
E Saland et al
7
Blood Cancer Journal
